Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Sell Good Start Genetics' Carrier Screening Test Service

NEW YORK (GenomeWeb) – Good Start Genetics said today that it has partnered with Roche Diagnostics to sell its carrier screening service for inherited disorders.

Under the agreement, Roche Diagnostics will offer Good Start's GeneVu carrier screening test along with its own Harmony noninvasive prenatal fetal aneuploidy test, which was developed by Ariosa Diagnostics.

"The agreement with Good Start Genetics will enable Roche to offer a broader range of screening services to healthcare professionals who provide care for pregnant women and for parents involved in planning a family," Whitney Green, senior vice president of commercial operations at Roche Diagnostics, said in a statement, adding that GeneVu will complement the Harmony test.

Both GeneVu and Harmony are only available as laboratory-developed tests in the US and have not been approved by the US Food and Drug Administration.

The GeneVu test identifies carriers of a number of inherited genetic disorders. It comes in different versions and uses next-generation sequencing as its underlying technology.

The announcement of the marketing agreement comes about a month after Good Start Genetics said that it is selling its VeriYou test, which screens only for carriers of cystic fibrosis and spinal muscular atrophy, through Amazon.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.